Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179643 · ClinicalTrials.gov registry record · Phase 1
AB-1002 in Patients With Class III Heart Failure
A Phase 1 study of Heart Failure and Cardiovascular Diseases, sponsored by AskBio.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT04179643: Active Phase 1 study of Heart Failure and Cardiovascular Diseases, sponsored by AskBio.
NCT04179643 is a Phase 1 study of Heart Failure and Cardiovascular Diseases that is active but no longer recruiting, run by AskBio. The registered enrollment target is 17 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04179643, a Phase 1 study of Heart Failure and Cardiovascular Diseases, is active but no longer recruiting, sponsored by AskBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up to 17 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured telephone questionnaires every 6 months for an additional 24 months (+/- 30 days).
Primary Outcome
Cardiopulmonary exercise testing using a modified Bruce protocol
Conditions Studied
Interventions
- BIOLOGICAL 3 x 10e13vg AB-1002
Study Locations (4)
Ohio
- The Linder Center for Education and Research at The Christ Hospital - Cincinnati
- The Ohio State University - Columbus
Minnesota
- Minneapolis Heart Foundation Institute - Minneapolis
Wisconsin
- University of Wisconsin at Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What the registry record for NCT04179643 still lists
NCT04179643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 9 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which 3 x 10e13vg AB-1002 is the first listed.
NCT04179643 reports a single indexed study location in Ohio, Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04179643 about?
NCT04179643 is a clinical study titled "AB-1002 in Patients With Class III Heart Failure". This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up...
What is the current status of trial NCT04179643?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-11-20. Estimated completion is 2026-09-30.
What conditions does trial NCT04179643 study?
This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Congestive Heart Failure, Heart Failure, Congestive, Heart Failure, Diastolic.
What interventions are being tested in trial NCT04179643?
The interventions under investigation include: 3 x 10e13vg AB-1002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04179643?
This trial is sponsored by AskBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179643 being conducted?
This trial has 4 study locations across Minnesota, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04179643's enrollment target sits among peer trials
17 366th of 397 higher than 30 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI